文献速递临床试验与 GCP流行病学与生物统计

美托洛尔预防前庭性偏头痛的随机对照试验(PROVEMIG)结果与经验教训

Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG).
PubMed 文献 · Trials · 2019-12-30

PROVEMIG是一项在德国八家大学医院开展的III期双盲随机安慰剂对照试验,计划纳入266例前庭性偏头痛患者,实际随机130例后因入组缓慢提前终止。美托洛尔缓释片95 mg/日与安慰剂相比,未发现前庭发作频率差异(发生率比0.983,95%CI 0.902-1.071),两组发作均随时间显著下降。

要点

  • 美托洛尔95 mg/日预防前庭性偏头痛发作未优于安慰剂。
  • 试验因入组缓慢提前终止,仅随机130例,未达计划样本量。
  • 两组前庭发作频率均随时间显著下降,提示需关注自然病程。

核心结论

  • 美托洛尔缓释片95 mg/日与安慰剂相比,未显示预防前庭性偏头痛发作的疗效优势。
  • 试验因入组缓慢提前终止,未达到计划样本量,无法确立治疗获益。

研究设计与样本

  • III期、双臂、平行组、双盲、随机安慰剂对照试验,在德国八家大学医院的神经科和耳鼻喉科开展。
  • 计划样本量266例,实际随机130例后终止;成人(≥18岁) probable或definitive前庭性偏头痛(Neuhauser 2001标准)按1:1随机分配。
  • 干预为6个月盲法美托洛尔(维持剂量95 mg/日)或安慰剂;主要疗效终点为每月前庭发作次数(纸質日记,第4-6个月)。

主要发现

  • 全分析集美托洛尔 vs 安慰剂的前庭发作发生率比为0.983(95%CI 0.902-1.071)。
  • 两组每月前庭发作总体随时间显著下降,因子为0.830(95%CI 0.776-0.887)。
  • 所有主观和客观关键疗效指标结果一致;治疗耐受性良好,无意外安全性发现。

临床怎么用

  • 不推荐美托洛尔95 mg/日用于预防前庭性偏头痛发作,因随机对照试验未证实优于安慰剂。
  • 前庭性偏头痛试验设计需考虑发作自然下降趋势,并开发经验证的有临床意义终点。

局限性

  • 试验因入组缓慢提前终止,实际样本量130例远低于计划266例,统计效能不足。
  • 主要终点依赖患者自报日记,可能存在报告偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vestibular migraine (VM) is the most frequent cause of recurrent spontaneous attacks of vertigo causally related to migraine. The objective of the Prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG) trial was to demonstrate that metoprolol succinate is superior to placebo in the prevention of episodic vertigo- and migraine-related symptoms in patients with VM. METHODS: This phase III, two-arm, parallel-group, double-blind, randomized placebo-controlled trial was designed to be conducted at tertiary referral centres at neurology and ear, nose and throat departments of eight German university hospitals. The planned sample size was a total of 266 patients to be allocated. Adults aged 18 years or above diagnosed with probable or definitive VM according to the Neuhauser criteria 2001 were randomly assigned 1:1 to 6 months blinded metoprolol (maintenance dosage of 95 mg daily) or placebo. The primary efficacy outcome was the self-reported number of vertiginous attacks per 30 days documented by means of a paper-based daily symptom diary. The pre-specified time period of primary interest was defined as months 4 to 6. Secondary outcomes included the patient-reported number of migraine days and vertigo days, the Dizziness Handicap Inventory, and clinical assessments. Adverse events were reported throughout the whole 9-month study period. RESULTS: At the time of trial termination, no evidence for a difference in the incidence of vertiginous attacks between groups was detected. For the full analysis set, the incidence rate ratio was 0.983 (95% confidence interval (CI) 0.902-1.071) for metoprolol versus placebo. In both groups, there was a significant decline over time in the overall monthly vertigo attacks by a factor of 0.830 (95% CI 0.776-0.887). Results were consistent for all subjective and objective key measures of efficacy. The treatment was well tolerated with no unexpected safety findings. CONCLUSIONS: After randomizing 130 patients PROVEMIG had to be discontinued because of poor participant accrual not related to the tolerability of the study medication or safety concerns; no treatment benefit of metoprolol over placebo could be established. Additional preparatory work is much needed in the development, psychometric evaluation and interpretation of clinically meaningful end points in trials on episodic syndromes like VM taking into consideration the complexity of this disease entity comprising two domains (vertigo- and headache-related disability). TRIAL REGISTRATION: EudraCT, 2009-013701-34. Prospectively registered on 8 April 2011.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Bayer O, Adrion C, Al Tawil A, et al. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials. 2019. PMID: 31888723. doi:10.1186/s13063-019-3903-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。